How many stocks are there of Incyte?
The current number of stocks of Incyte is 225.93 M undefined.
Incyte Stocks 2024
Incyte Stocks
225.93 M
Incyte Dividend yield
Ticker
INCY
ISIN
US45337C1027
WKN
896133
In 2024, Incyte had 225.93 M outstanding stocks, a 0% change from the 225.93 M stocks in the previous year.
The Incyte Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 225.93 |
| 2028e | 225.93 |
| 2027e | 225.93 |
| 2026e | 225.93 |
| 2025e | 225.93 |
| 2024e | 225.93 |
| 2023 | 225.93 |
| 2022 | 224 |
| 2021 | 222.1 |
| 2020 | 218.1 |
| 2019 | 217.7 |
| 2018 | 215.6 |
| 2017 | 204.6 |
| 2016 | 194.1 |
| 2015 | 187.3 |
| 2014 | 167.9 |
| 2013 | 148.4 |
| 2012 | 129.7 |
| 2011 | 125.4 |
| 2010 | 121.6 |
| 2009 | 102.9 |
| 2008 | 89.8 |
| 2007 | 84.2 |
| 2006 | 83.8 |
| 2005 | 83.3 |
| 2004 | 74.6 |
Incyte Aktienanalyse
What does Incyte do?
The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Incyte revenue by segment
In the annual report of the Incyte share (US45337C1027, 896133, INCY), it breaks down its revenues into 3 segments: 1. Product, 2. Product Royalty, 3. Milestone & Contract. The Incyte stock (WKN: 896133, ISIN: US45337C1027, Ticker Symbol: INCY) is a leading investment for investors interested in participating in the Health Care sector.
Stocks Details
Evaluating Incyte's Shares Outstanding
Incyte's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Incyte’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Incyte’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Incyte’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Incyte Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Incyte are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Incyte evolved in recent years?
The number of shares of Incyte has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Incyte as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Incyte?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Incyte pay?
Over the past 12 months, Incyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Incyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Incyte?
The current dividend yield of Incyte is .
When does Incyte pay dividends?
Incyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Incyte?
Incyte paid dividends every year for the past 0 years.
What is the dividend of Incyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Incyte located?
Incyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Incyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Incyte from 4/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/29/2024.
When did Incyte pay the last dividend?
The last dividend was paid out on 4/29/2024.
What was the dividend of Incyte in the year 2023?
In the year 2023, Incyte distributed 0 USD as dividends.
In which currency does Incyte pay out the dividend?
The dividends of Incyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Incyte stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Incyte
Our stock analysis for Incyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Incyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
